BioRegnum: Another great reason emerges for AstraZeneca to target new biotech deals
Bioregnum
The view from Endpoints
The pressure on AstraZeneca CEO Pascal Soriot to get its global R&D operation to perform while executing new deals just soared. The pharma giant has lost a bid to keep cheap generic versions of Crestor off the market. That drug earned some $5 billion of the $23 billion it made last year.
To put this into a perspective that must be increasingly uncomfortable at the pharma giant, AstraZeneca will soon have a new, blockbuster-sized hole to fill as investors continue to insist that the company keep its promise to hit $45 billion in sales in just seven more years.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.